Form 4: Quest Diagnostics Executive Reports Stock Acquisition

SVP of Clinical Solutions Karthik Kuppusamy acquired 39 shares of Quest Diagnostics common stock via a dividend reinvestment plan.

Summary

• Karthik Kuppusamy, SVP of Clinical Solutions at Quest Diagnostics, acquired 39 shares of common stock at a price of $194.699 per share.
• The acquisition was executed on April 20, 2026, through a dividend reinvestment plan.
• Following this transaction, the reporting person holds 13,490 shares directly, with additional indirect holdings of 1,751 shares in a 401(k) plan and 358 shares held in a trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding personal stock ownership.

Positives

• The reporting person continues to increase their equity stake in the company, signaling alignment with shareholder interests.

Negatives

• None identified; this is a routine transaction related to a dividend reinvestment plan.

Risks

• None identified; this filing pertains to routine personal investment activity.

Future Outlook

No forward-looking guidance or strategic outlook provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider acquisitions via dividend reinvestment plans are standard corporate governance practices and do not typically signal shifts in company strategy or market outlook.

Comparison to Industry Standards

• The transaction is consistent with standard executive compensation and equity participation programs observed in large-cap healthcare companies like LabCorp or HCA Healthcare.

Stakeholder Impact

• Minimal impact on shareholders as the transaction is a small-scale dividend reinvestment.

Next Steps

• None; this is a completed transaction report.

Key Dates

Keywords

Quest Diagnostics, DGX, Insider Trading, Form 4, Dividend Reinvestment, Equity Ownership